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Depletion of RIPK3 or MLKL blocks TNF-driven
necroptosis and switches towards a delayed RIPK1
kinase-dependent apoptosis
Q Remijsen1,2, V Goossens1,2, S Grootjans1,2, C Van den Haute3, N Vanlangenakker1,2, Y Dondelinger1,2, R Roelandt1,2,
I Bruggeman1,2, A Goncalves4, MJM Bertrand1,2, V Baekelandt3, N Takahashi1,2, TV Berghe1,2 and P Vandenabeele*,1,2
In human cells, the RIPK1–RIPK3–MLKL–PGAM5–Drp1 axis drives tumor necrosis factor (TNF)-induced necroptosis through
mitochondrial fission, but whether this pathway is conserved among mammals is not known. To answer this question, we
analyzed the presence and functionality of the reported necroptotic axis in mice. As in humans, knockdown of receptor-
interacting kinase-3 (RIPK3) or mixed lineage kinase domain like (MLKL) blocks TNF-induced necroptosis in L929 fibrosarcoma
cells. However, repression of either of these proteins did not protect the cells from death, but instead induced a switch from
TNF-induced necroptosis to receptor-interacting kinase-1 (RIPK1) kinase-dependent apoptosis. In addition, although
mitochondrial fission also occurs during TNF-induced necroptosis in L929 cells, we found that knockdown of phosphoglycerate
mutase 5 (PGAM5) and dynamin 1 like protein (Drp1) did not markedly protect the cells from TNF-induced necroptosis. Depletion
of Pink1, a reported interactor of both PGAM5 and Drp1, did not affect TNF-induced necroptosis. These results indicate that in
these murine cells mitochondrial fission and Pink1 dependent processes, including Pink-Parkin dependent mitophagy,
apparently do not promote necroptosis. Our data demonstrate that the core components of the necrosome (RIPK1, RIPK3 and
MLKL) are crucial to induce TNF-dependent necroptosis both in human and in mouse cells, but the associated mechanisms may
differ between the two species or cell types.
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Necroptosis is a form of regulated necrosis that strictly
depends on the kinase activity of receptor-interacting
kinase-1 (RIPK1) and receptor-interacting kinase-3 (RIPK3).1
This cell death modality operates independently of execu-
tioner caspases, but is negatively regulated by caspase-8 and
therefore is sensitized under conditions of caspase-8 inhibi-
tion or deficiency.2 Necroptosis was first observed in L929
murine fibrosarcoma cells as a regulated form of cell death.2
But only with the recent availability of necrostatins3 and
RIPK3 knockout mice4 was its importance noted in various
pathologies, including ischemia/reperfusion,5,6 inflammatory
bowel disease,7,8 viral infection,9 Salmonella infection10
and sepsis.11
The involvement of functional necroptosis in vivo greatly
relies on the use of RIPK1 kinase inhibitors such as
necrostatins3,5 and the discovery of RIPK3 as a decisive
pro-necroptotic kinase.9,12,13 Members of the tumor necrosis
factor (TNF) family are potent inducers of necroptosis. TNF-
induced necroptosis involves the formation of a necrosome
complex consisting of the core components RIPK1, RIPK3
and mixed lineage kinase domain like (MLKL) that are
negatively regulated by factors such as Fas associated death
domain protein (FADD), caspase-8 and cellular FLICE
inhibitory protein.1,14 Despite the importance of necroptosis,
its molecular components and the mechanisms of its
regulation and execution remain elusive. Until recently, the
only known downstream substrates of RIPK1 andRIPK3 have
been RIPKs serving as their own substrates.9 But last year
two novel RIPK3 substrates were reported: mixed lineage
kinase domain like (MLKL)15,16 and phosphoglycerate
mutase 5 (PGAM5).17
MLKL was independently identified by two different groups,
who showed that it is constitutively bound by a wild type but
not by the kinase-dead RIPK3.15,16 During TNF-induced
necroptosis, RIPK3 phosphorylates humanMLKL at positions
T357 and S358, and these phosphorylations were shown to
be essential for TNF-induced necroptosis.15 Although Zhao
et al.16 identified MLKL by screening a short hairpin library
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against kinases/phosphatases in HT-29 cells, Sun et al.15
identified MLKL by screening a large library of compounds
against TNF-necroptosis in HT-29 cells and showed that
necrosulfonamide (NSA) inhibits TNF-driven necroptosis.
Biotinylated NSA was subsequently used to pull down and
identify MLKL.15 Importantly, the Cys86 residue in human
MLKL – which is targeted by NSA – is absent in murine
MLKL.15 Consequently, NSA does not delay necroptosis in
murine cells.15
The second reported RIPK3 substrate is PGAM5.17 In
humans, the PGAM5 gene encodes two isoforms, PGAM5-L
and PGAM5-S, produced by alternative splicing.18 PGAM5
constitutively translocates to the mitochondria and has
phosphatase activity, but other PGAM members involved in
glucose metabolism do not have these properties.19 The
phosphorylation of PGAM5 during TNF-driven necroptosis
has been shown to require RIPK3.17 In turn, phosphorylated
PGAM5 activates the mitochondrial fission protein, dynamin
related kinase-1 (Drp1), by dephosphorylating S637, which
then allows Drp1-driven mitochondrial fission.17 It has thus
been proposed that RIPK3 activates the MLKL–PGAM5–
Drp1 axis during necroptosis. The observed mitochondrial
fission would thereby serve as a potential execution mecha-
nism during TNF-driven necroptosis.17
In this study, we chose to further examine the contribution of
the components of this novel17 axis in a prototype murine
model of necroptosis. We also included Pink1, as this protein
is reported to interact with PGAM520 as well as Drp1,21
influence cell death22 and affect mitochondrial fission.23 Pink1
also regulates the removal of damaged mitochondria in a
process calledmitophagy.24 This cellular function requires the
E3 ubiquitin ligase Parkin, a downstream regulator of Pink1.25
Therefore, we studied a possible contribution of Parkin in
TNF-induced necroptosis as well.
Overall, our data show that knockdown of RIPK1, RIPK3 or
MLKL strongly attenuates TNF-induced necroptosis in murine
cells. In contrast, repression of PGAM5, Pink1 or Parkin has
no effect on necroptosis induction, and Drp1 knockdown only
mildly delays TNF-induced necroptosis. These data indicate
that neither mitochondrial fission nor mitophagy contribute to
the execution of TNF-induced necroptosis in our murine
cellular system. Of interest, absence of RIPK3 or MLKL not
only blocks necroptosis but also shifts the response to RIPK1
kinase-dependent apoptosis.
Results
Knockdown of RIPK3 or MLKL blocks TNF-induced
necroptosis and reveals a switch to apoptosis that is
dependent on RIPK1 kinase activity. The RIPK1–RIPK3–
MLKL–PGAM5–Drp1 axis operates during TNF/zVAD-fmk-
induced necroptosis in the presence of SMAC mimetics (SM)
in human HT-29 cells and HeLa cells transfected with
RIPK3.15 It is unknown whether this pathway is conserved
among mammalian cells and to which extent it influences
induced apoptosis. The murine L929 fibrosarcoma cell
line has been the prototype cellular model system for
identifying pathways involved in necroptosis.2,9,12,13,26,27
It allows TNF-induced necroptosis without the need for
adding IAP inhibitors such as SM, or caspase inhibitors
such as zVAD-fmk. Therefore, we studied the contribution of
the recently identified axis to TNF-induced necroptosis in
murine L929 cells. In addition, we also studied its possible
contribution to anti-Fas-induced apoptosis. To identify
potential cell death modality switches upon interference with
either cell death pathway, we simultaneously monitored cell
death and caspase activity as a function of time. Knockdown
of none of the members of the RIPK1–RIPK3–MLKL–
PGAM5–Drp1 axis affected Fas-induced apoptosis, which
was visualized by cleavage of a synthetic caspase substrate
(Figures 1a and b, right axis) and disruption of the plasma
membrane (Figures 1a and b, left axis). As we showed in a
previous study,14 knockdown of RIPK1 (Figure 1c) did not
block TNF-induced cell death but shifted cell death from
TNF-induced necroptosis to apoptosis (Figure 1a). Knock-
down of MLKL (Figure 1d) significantly delayed TNF-induced
necroptosis in L929 cells 6 h after TNF stimulation
(Figure 1a), as previously reported for L929 cells.15,16
Interestingly, we now show that this delayed cell death is
associated with caspase activity (Figures 1a and b),
indicating a shift to apoptosis. Apoptosis was confirmed by
detecting chromatin condensation and plasma membrane
blebbing (Figure 2a). Knockdown of RIPK3 (Figure 1c)
completely blocked TNF-induced necroptosis until 6 h
after stimulation (Figure 1a). However, cell death observed
later was also associated with an increased caspase
activity (Figure 1b), indicating a switch to apoptosis as
well. Importantly, this TNF-induced apoptosis observed
upon knockdown of RIPK3 or MLKL was reduced in the
presence of the RIPK1 kinase inhibitor necrostatin-1
(Figure 2b), demonstrating its dependence on the kinase
activity of RIPK1.
Evaluation of the possible contribution of the PGAM5–Drp1
axis in TNF-induced necroptosis in L929 cells. Remarkably,
and in contrast to TNF-induced necroptosis in HeLa cells
transfected with RIPK3,17 knockdown of PGAM5 (Figure 1d)
did not influence necroptosis in L929 cells (Figures 1a and b
and Supplementary Figure S1). Knockdown of the reported
PGAM5 target Drp117 was very effective (Figure 1c),
but it resulted only in a mild but significant delay of
TNF-necroptosis (Figure 1a and Supplementary Figure S1).
Note that knockdown of Drp1 markedly slowed down cell
proliferation (Figures 3a and b). This was not observed for
any other protein examined in this study. We therefore
addressed whether the delay in cell proliferation and/or the
delay in cell death caused by Drp1 knockdown could be
attributed to a decrease in mitochondrial metabolism, which
is known to protect from necroptosis.13,28,29 However,
knockdown of Drp1 did not reduce mitochondrial respiration
(Figure 3c), whereas pharmacological inhibition of Drp1 using
mitochondrial division inhibitor (mdivi)30 did (Figure 4a).
The Drp1 inhibitor mdivi markedly delayed TNF-driven
necroptosis (Figure 4b), in line with the results obtained
in human cells.16 The protective effects of mdivi on
TNF-induced necroptosis contrast with the mild protection
observed after Drp1 knockdown (Figures 1a and b and
Supplementary Figure S1). Note that this delay only occurred
when mdivi was used at concentrations that also block
mitochondrial respiration (Figures 4a and b).
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These data suggest that mdivi delays TNF-driven necroptosis
because it inhibits mitochondrial respiration rather than
mitochondrial fission. In addition, the unaffectedmitochondrial
respiration upon Drp1 knockdown suggests that mdivi inhibits
mitochondrial respiration due to off-target effects indepen-
dently from targeting Drp1. This illustrates that the effect of
mdivi in this context of necroptosis cannot be confined
to its inhibitory activity on Drp1. In conclusion, our data
Figure 1 Transient knockdown of components along the RIPK1–RIPK3–MLKL–PGAM5–Drp1 axis in L929sahFas cells. Knockdown of RIPK1, RIPK3 or MLKL causes a
switch from TNF-induced necroptosis to apoptosis. Seventy-two hours after knockdown of L929sahFas cells with the indicated siRNAs, cells were stimulated in triplicate with
TNF (10 000 U/ml) or in duplicate with agonistic anti-Fas Ab (250 ng/ml). (a) The 6-h time point is shown±S.E.M (n¼ 3). Cell death and caspase activity were determined as
described in Materials and Methods. *Po0.05 and **Po0.01. (b) The 12-h time point is shown±S.E.M (n¼ 3). Cell death and caspase activity were determined as
described in Materials and Methods. *Po0.05. (c) Seventy-two hours after knockdown of murine RIPK1, RIPK3, Drp1 or Parkin, the knockdown efficiency of these targets was
validated by western blotting, and (d) 72 h after knockdown of murine PGAM5, MLKL and Pink1, the knockdown efficiency of these targets was validated by RT-PCR because
detection by antibody was unreliable
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demonstrate that knockdown of PGAM5 or Drp1 hardly
affects TNF-induced necroptosis in L929 cells. Indeed,
kinetics of TNF-necroptosis remain intact upon knockdown
of PGAM5 and are mildly delayed upon knockdown of Drp1
(Supplementary Figure S1). It remains possible that the
observed delay of cell proliferation upon Drp1 knockdown
contributes to this mild protection from TNF-necroptosis.
Evaluation of the possible contribution of the PGAM5–
PINK1–Parkin axis in TNF-induced necroptosis. We also
examined the possible contribution of Pink1, a genetic
interactor of PGAM520 and Drp121 and an upstream regulator
of Parkin.25 Transient knockdown of Pink1 markedly delayed
TNF-necrosis without a shift toward apoptosis (Figure 1a),
whereas stable knockdown of Pink1 did not affect TNF-
necroptosis (Supplementary Figure S2). Given these different
outcomes, we examined a possible pro-necroptotic role
of Pink1 using two additional approaches. In the first
approach, we found that inducible overexpression of a wild-
type Pink1 that is resistant to siRNAs targeting Pink1 could
not revert the protective phenotype of siRNAs targeting
murine Pink1 (Supplementary Figure S3 and Supplementary
Data D1). These data suggest that off-target effects of the
siRNAs targeting Pink1 are responsible for their protective
effects against TNF-necroptosis. In a second complementary
approach, we observed no significant differences in TNF/
Tak1i/zVAD-fmk-induced cell death between Pink1 KO MEFs
and littermate control MEFs (Supplementary Figure S4),
indicating that Pink1 has no role in necroptosis.
Finally, we found that knockdown of Parkin (Figure 1c),
a downstream effector of Pink1 in the induction of mitophagy,
did not affect TNF-necroptosis (Figures 1a and b and
Supplementary Figure S1). Because both Pink1 and Parkin
did not seem to contribute to TNF-induced necroptosis, we
monitored the occurrence of mitophagy, which is preceded by
depolarization of mitochondrial membranes. For this purpose,
we performed live cell imaging of L929 cells expressing
mitochondrially targeted GFP. Within 1–3 h after TNF
stimulation, the tubular mitochondrial network of mito-GFP
disintegrated in a punctate pattern (Supplementary Figure S5).
Importantly, these punctate mito-GFP structures retained
their mitochondrial membrane potential, assessed by staining
with the mitochondrial potential dye TMRM (Supplementary
Figure S5). Consequently, depolarization of mitochondrial
membranes, a prerequisite for mitophagy, did not occur
during TNF-necroptosis. Altogether, these data argue
against the involvement of Pink1–Parkin dependent
processes, including mitophagy, in regulating the execution
of TNF-necroptosis.
Discussion
We used a murine model of necroptosis to study the
contribution of components of the recently identified RIPK1–
RIPK3–MLKL–PGAM5–Drp1 axis17 promoting mitochondrial
fission during TNF-induced necroptosis. We also examined
whether Pink1, a genetic interactor of PGAM520 and Drp1,21
known to affect mitochondrial fragmentation,23 influences
necrotic cell death.
Following TNF stimulation, different types of complexes are
formed.31 Complex I mediates NF-kB activation and MAPK
signaling, resulting in inflammation and cell survival. The
cytosolic complex II initiates FADD-caspase-8-mediated
apoptosis, which under cIAP-depleting conditions can be
either independent of the RIPK1 kinase activity (so-called
complex IIa) or dependent on it (so-called complex IIb).
Typically, RIPK1/3 are inactivated by caspase-8-mediated
cleavage, resulting in suppression of necroptosis. When
caspase-8 is inhibited or absent, complex II initiates necrop-
tosis, which is dependent on RIPK1–RIPK3–MLKL.15
Uniquely in L929 fibrosarcoma cells, TNF directly induces
necroptosis without the need to block caspase-8, which is
functionally present.2 We previously have shown that depletion
of RIPK1 shifts TNF-induced necroptosis to an accelerated
form of apoptosis that is not inhibited by Nec-1 as its target
(RIPK1) is depleted.14 These results demonstrate that
Figure 2 Knockdown of RIPK3 or MLKL results in delayed cell death that switches from TNF-induced necroptosis to a delayed, Nec-1 sensitive apoptosis. (a) Seventy-two
hours after knockdown of L929sahFas cells with the indicated siRNAs, cells were stimulated with TNF (10 000 U/ml) or agonistic anti-Fas Ab (250 ng/ml) in the presence of
1mg/ml HOECHST and 3 mg/ml propidium iodide (PI). Imaging was performed on a BDPathwayTM 855 (n¼ 2). Chromatin condensation is indicated with arrows and plasma
membrane blebbing with arrowheads. Scale bar indicates 20 mm. (b) Seventy-two hours after knockdown of L929sahFas cells with the indicated siRNAs, cells were pretreated
with 10mM necrostatin-1 (N1) for 1 h, followed by TNF stimulation (10 000 U/ml) in triplicate. Cell death and caspase activity were determined as described in Materials and
Methods. The 12-h time point is shown±S.E.M (n¼ 3)
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RIPK1 negatively controls FADD-caspase-8 mediated apop-
tosis. As TRADD and RIPK1 can compete for TNFR-1 binding
in complex I, the absence of RIPK1 probably facilitates the
interaction of pro-apoptotic proteins, including TRADD, with
the TNFR1 and the formation of complex IIa.32–35 Here, we
show that depletion of RIPK3 or MLKL also shifts TNF-
induced necroptosis to apoptosis, albeit with a delay. These
results may indicate that RIPK3 and MLKL, like RIPK1,
negatively control FADD-caspase-8-mediated apoptosis.
Alternatively, RIPK3 and MLKL may just ensure efficient
pro-necroptotic signaling, and in their absence apoptosis
becomes the default outcome of triggering a cell death
pathway. We also observed that the delayed apoptosis upon
depletion of RIPK3 orMLKL can be inhibited byNec-1. RIPK1-
kinase-dependent apoptosis was also observed in the
presence of IAP inhibitors and TNF,36 etoposide,37,38 TRAIL39
or in the presence of Tak1 inhibitor and TNF.14,40 These data
confirm that RIPK1 kinase activity is involved in both
apoptosis and necroptosis. This switch from necroptosis to
RIPK1-mediated apoptosis after depletion of RIPK3 andMLKL,
Figure 3 Knockdown of Drp1 delays cell proliferation but does not reduce mitochondrial respiration. (a) Forty-eight hours after transient knockdown of L929 cells with the
indicated siRNAs, cells were seeded at 10 000 cells in a 96-well plate (eight replicates), and after 24 h live cells (Hoechstþ /PI-) were counted using automated imaging.
Data are expressed as percentage of control±S.E.M (n¼ 3). *Po0.05. (b) Forty-eight hours after reverse transfection of L929 cells with the indicated siRNAs, cells were
seeded at 10 000 cells in a 96-well plate, and 24 h later the cells were incubated in fresh medium supplemented with SytoxGreen (1.6 mM) and Triton-X100 (0.1% w/v).
Subsequently, maximal fluorescence of Sytoxgreen was determined by fluorometry. Data are expressed as percentage of control±S.E.M (n¼ 3). *Po0.05. (c) Basal,
maximal and minimal oxygen consumption rates (OCR) in L929 cells were analyzed as described in Materials and Methods. Briefly, 10 000 cells were seeded in a 96-well plate
(eight replicates) for each knockdown. After 24 h, cellular oxygen consumption rates were determined. The data show the kinetics of four consecutive measurements of
baseline respiration. Subsequently, the protonophore CCCP was added (12 mM) to each well to dissipate the mitochondrial membrane potential and thereby promote
maximal electron transport and corresponding maximal oxygen consumption. Injection of the complex I inhibitor rotenone (Rot, 2.5 mM) and complex III inhibitor
Antimycin-A (AM, 5 mM) in each well was followed by four consecutive measurements (at 5 min intervals) to determine the minimal mitochondrial respiration. Finally, the
amount of viable cells (HOECHSTþ /PI- cells) in the microchamber of each well was determined by automated imaging. The data represent the oxygen consumption rate
(pmol O2 per minute) per 1000 cells±S.E.M (n¼ 3)
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at least in L929 fibrosarcoma cells, should be taken into
consideration when developing strategies for interfering with
necroptosis induction. Note that the difference in induction
rate of apoptosis between RIPK1 and RIPK3/MLKL knock-
downmay be due to the contribution of RIPK1within complex I
to NF-kB activation, resulting in defective induction of cell
death inhibitory proteins such as Bcl-2 members and IAPs,
leading to cell death ‘without brakes’.
Downstream of the RIPK1–RIPK3–MLKL axis, PGAM5 and
Drp1 might function as executioners of necroptosis by
activating mitochondrial fission.16 However, knockdown of
PGAM5 did not alter TNF-necroptosis in the murine L929
necroptosis system, in contrast to human cells.17 Our results
are in agreement with the recent report of Murphy et al.41, who
showed that stable knockdown of PGAM5 did not affect TNF-
driven necroptosis in both L929 andMEF cells. One possibility
is that PGAM5 is a stable protein, and its knockdown at the
RNA level does not guarantee the absence of sufficient
functional PGAM5 protein. Alternatively, PGAM5 might not
regulate TNF-induced necroptosis in murine cells. In this
regard, it is noteworthy that PGAM5 exists in two splice
variants in human cells, PGAM5-L and PGAM5-S.18 Knock-
down of both variants in human HT-29 cells was recently
reported to protect against TNF-induced necroptosis.17 This
protective phenotype could not be rescued by reintroduction
of PGAM5-L alone, but required reintroduction of PGAM5-S
as well.16 The fact that murine cells express PGAM5-L but not
PGAM5-S might explain why a pro-necroptotic role could not
be confirmed for PGAM5 in murine cells. In line with this
statement is that efficient knockdown of the reported target of
PGAM5, namely Drp1, caused only a small delay in TNF-
necroptosis. This suggests a minor role for Drp1 and Drp1-
mediated processes in TNF-induced necroptosis, such as
mitochondrial fragmentation. In apparent contrast with this
conclusion is the observation that addition of the Drp1 inhibitor
mdivi protected against TNF-necroptosis, in line with a
previous report by Wang et al.17 Overall, we conclude that
at least in mouse cells the supposed Drp1 inhibitor mdvi
protects from TNF-induced necroptosis by preventing respira-
tion rather than inhibiting Drp1.
We also examined whether Pink1, a genetic interactor of
PGAM520 and Drp1,21 influences necrotic cell death. Pink1 is
known to affect mitochondrial fragmentation.23 In addition,
Pink1 is involved in the removal of damaged mitochondria
through regulation of its downstream effector Parkin,22
a ubiquitylating enzyme regulating mitophagy.25 Transient
knockdown of Pink1 apparently delayed TNF-necroptosis
without shifting to apoptosis, suggesting that Pink1 might be a
positive regulator of TNF-necroptosis. This is an unexpected
finding as Pink1 is generally reported to promote survival.
Therefore, we examined the phenotype of pink1 /MEF in
TNF/Tak1i/zVAD-fmk-mediated necroptosis. Knockout of
Pink1 did not affect necroptosis induction. How can this be
reconciled with the apparent role of Pink1 in the first
experiment? We could pinpoint the effect of the Pink1 siRNA
to an off-target effect by reconstituting a mutated Pink1 that
could not be knocked down. The siRNA still displayed delayed
necroptosis despite the presence of non-targetable Pink1,
which is in agreement with the inability of stable knockdown
of Pink1 to affect TNF-necroptosis. Transient knockdown of
Parkin, a downstream effector of Pink1, also did not affect
TNF-necroptosis. Overall, these results indicate that
processes that depend on Pink1 and Parkin, including
mitophagy, are probably not important regulators of
TNF-necroptosis. And although mitochondrial fission does
occur during TNF-necroptosis, the absence of a protective
effect after knockdown of PGAM5, Drp1, Pink1 or Parkin
suggests that mitochondrial fission is probably more of a
Figure 4 The Drp1 inhibitor mdivi inhibits TNF-induced necroptosis and mitochondrial respiration. (a) L929sahFas cells were pretreated with mdivi (0–250mM) for 1 h and
respiration was analyzed as described in Materials and Methods. After four consecutive measurements of basal respiration, the protonophore CCCP was injected (12mM) and
maximal respiration was determined. Rotenone (2.5mM) and Antimycin-A (5 mM) were then injected to determine the mitochondrial baseline respiration. A representative
experiment is shown (n¼ 2). (b) After pretreatment with mdivi (0–250mM), L929sahFas cells were stimulated with TNF for 6 h, and cell death was determined by flow
cytometry; it is expressed as percentage of SytoxGreen positive cells control±S.E.M (n¼ 2). *Po0.05
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bystander phenomenon than a causal executor of TNF-
necroptosis.
Altogether, our data show that not only knockdown of
RIPK1, but also of the other two necrosome members RIPK3
and MLKL, blocks necroptosis and shifts the cell death
modality to apoptosis, which is dependent on the kinase
activity of RIPK1. None of the other supposed downstream
necrosome interactors (PGAM5, Drp1) induced this switch,
indicating that MLKL is the most downstream effector of
necroptosis reported to induce this switch upon knockdown.
It is obvious that these switches would be overlooked when
studying cellular models of necroptosis that require the use of
pan-caspase inhibitors or caspase depletion, as in many
studies based on MEF cells. A major advantage of L929 cells
is that TNF directly triggers necroptosis in the absence of pan-
caspases inhibitors, whereas apoptotic signaling remains
possible. We are convinced that the observed switches to
apoptosis are of much importance in the search for drugs that
are more specific for necroptosis by targeting RIPK3 and/or
MLKL. Genetic knockdown and pharmacological inhibition do
not always produce the same phenotype, especially when the
proteins concerned have platform functions in addition to their
enzymatic activities. Nec-1, for example, targets RIPK1 but
does not induce a switch from TNF-driven necroptosis to
apoptosis. Unfortunately, the recently reported inhibitor of
MLKL, NSA, only targets human but not murine MLKL, and so
far has been studied only in cellular models of necroptosis
requiring caspase inhibition. It therefore remains to be shown
in other necroptosis cellular systems, that are independent of
caspase inhibitors, whether inhibition of MLKL can rescue
cells from death as the cell death signal may switch to RIPK1-
mediated apoptosis.
Materials and Methods
Materials. Recombinant human TNF, produced and purified to at least 99%
homogeneity in our laboratory, has a specific biological activity of 3 107 IU/mg.
Agonistic anti-human Fas (clone 2R2) was from Cell Diagnostica (Munster,
Germany). zVAD-fmk was from Bachem (Bubendorf, Switzerland). Nec-1 was
from Calbiochem (San Diego, CA, USA). The Tak1 inhibitor NP-009245 was
purchased from AnalytiCon Discovery GmbH (Potsdam, Germany). Ac-DEVD-amc
was from PeptaNova GmbH (Sandhausen, Germany). CCCP, Rotenone and
Antimycin-A were purchased from Sigma Aldrich (Steinheim, Germany). NSA
was from Toronto Research Chemicals (Toronto, ON, Canada). The Drp1
inhibitor mdivi was from Merck Chemicals Ltd (Nottingham, UK). Anti-b-actin
(clone C4; MP BiomedicalsEurope NV, Illkirch, France), anti-Parkin (sc-32282)
and anti-MLKL (sc-130172) were from Santa Cruz Biotechnology (Santa Cruz,
CA, USA), anti-RIP1 from BD Biosciences (610459; Franklin Lakes, NJ, USA),
and anti-RIP3 (R4277) and anti-MLKL (M6697 and SAB1408428) from
Sigma Aldrich. Anti-Drp-1 was from BD Transduction laboratories (clone
8/DLP1, Franklin Lakes, NJ, USA).
Live cell imaging. Live cell imaging of L929sahFas cells stably expressing
mito-GFP was performed on an AS-MDW workstation from Leica (Wetzlar,
Germany). One day before imaging, 40 000 cells were seeded in a borosilicate
eight-chamber plate. Next, the medium was replaced with a medium containing
50 nM TMRM and 50mM SytoxRed (SR) for 1 h. Cells were then stimulated with
TNF and fluorescence (75-W Xenon burner with monochromator set at 2 mW),
and DIC images were taken every 5min. Phototoxicity and photobleaching were
prevented by minimizing the exposure time for fluorescence excitation (o100ms)
and setting the camera at gain 2 and 2 2 binning. Different focal planes were set
at 1 mm intervals. From each image stack, maximum intensity projections (for SR,
mito-GFP and TMRM) were made by using a script developed in-house for ImageJ
1.31i public domain imaging software. The 3D deconvolution (iterative restoration
based on calculated PSFs) was performed on Image sequences of mito-GFP and
TMRM using the Volocity software 5.2.0. Subsequent montages of the Multi-tiff
time series and three-channel overlays were made in ImageJ 1.31i.
Cell culture. L929sAhFas cells were generated as previously described.2
L929sahFas with stable knockdown of Pink1 were generated by cloning short
hairpins targeted against 30UTR of Pink1 in GATEWAY compatible pcDNA6.2-
GWþ EmGFP-miR (BLOCK-iT Pol II miR RNAi Expression Vector, Sigma
Aldrich), according to the manufacturers instructions. Of the 10 sequences
targeted in the 30UTR in Pink1, knockdown was achieved by targeting the 30UTR
sequence cgtccagttaggttcttggg (seq 1) and accaggagttggtaagctata (seq 2)
(Supplementary Data D1). pLenti6 expressing shPink1-EmGFP or mito-GFP
was introduced in L929sahFas cells as described previously.29 All cell lines were
cultured in DMEM supplemented with 10% fetal calf serum, penicillin (100 IU/ml),
streptomycin (0.1 mg/ml), and L-glutamine (0.03%). Primary, non-immortalized
MEFs were isolated and pooled from eight embryos of Pink1 KO mice or control
littermates, as described previously.23
RNAi-mediated knockdown. L929sahFas cells were transfected in six-well
plates according to manufacturer’s protocol as described previously.28
Knockdown was validated by RT-PCR or wherever possible, also by western
blotting. Because none of the three antibodies against MLKL could reliably detect
MLKL in western blots, we were compelled to validate knockdown of MLKL on the
mRNA level. Reliable antibody detection is considered as clear detection of a band
of expected molecular weight, of which the intensity can be reduced by
knockdown, when knockdown efficiency was already confirmed by qPCR.
Cell death and caspase activity analysis. Cell death was analyzed on
a FLUOSTAR Omega (BMG Labtech, Offenburg, Germany). Ten thousand cells
were seeded in a transparent 96-well plate. Next day, DMEM was replaced with
DMEM containing a 1.6mM SytoxGreen (SG) and 33mM Ac-DEVD-amc, and the
cells were incubated with various inhibitors for 1 h. Next, cells were stimulated with
TNF (10 000 U/ml) or agonistic anti-Fas Ab (250 ng/ml). Maximal cell death was
obtained by treatment with Triton-X100 (0.05%). This allows expression of cell
death as percent of control of maximal SG fluorescence (excitation 485 nm,
emission 520 nm). If executor caspases-3/-7 were activated during cell death, they
cleave ac-DEVD-amc only upon plasma membrane rupture. The release of
fluorescent 7-amino-4-methylcoumarin (amc) was monitored (excitation 355 nm,
emission 460 nm). Alternatively, cell death was analyzed on a BDPathwayTM 855
instrument (BD Biosciences) as described previously11 and by flow cytometry as
previously described.29
Mitochondrial respiration. Mitochondrial oxygen consumption in the
Leibovitz medium containing 1% FCS was measured in a Seahorse XF96-
Analyzer (Seahorse Bioscience, Billerica, MA, USA). Oxygen consumption rates
were analyzed following manufacturer’s protocols. Measurements are based on
oxygen-dependent quenching of a built-in fluorescent sensor. After four
measurements of basal respiration, CCCP was injected (12 mM) and maximal
respiration was determined. Rotenone (2.5mM) and Antimycin-A (5mM) were then
injected to determine the mitochondrial baseline respiration. Subsequently,
the amount of cells in the microchamber of each well was determined
on a BDPathwayTM 855 instrument as described previously.11 This allows
normalization of the respiratory rates in function to the amount of cells in each
microchamber.
Statistics. Using GraphPad Prism Version 6 (San Diego, CA, USA), data were
analyzed by one-way ANOVA and a Tukey multiple comparison test, unless
indicated otherwise. Statistical significance was accepted at Po0.05, number of
independent experiments are mentioned and all error bars indicate standard error
of the mean, unless otherwise indicated.
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